News
COVID Concerns: FDA’s New Vaccine Guidelines Raise Questions
Last week, FDA Commissioner Dr. Marty Makary and Dr. Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research, outlined the agency’s new approach to COVID shots in an article published in the New England Journal of Medicine.
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
What you need to know about Moderna’s new COVID vaccine, just approved by the FDA
Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID vaccine, but only for specific populations: all adults 65 and over and those between 12 and 64 with at least one underlying risk factor as defined by the Centers for Disease Control and Prevention.
Federal health officials have changed the game for COVID vaccine access. Pregnant moms and others who rely on them to protect a high-risk family member are scared.
For children, yes, the CDC’s “shared decision-making” guidance preserves the status quo in which Medicaid and U.S.
Uncertainty now dominates the COVID vaccine outlook after official recommendations were stripped for a variety of groups.
As promised, federal health officials this week dropped longstanding recommendations that healthy children and healthy ...
RFK Jr. will no longer recommend annual COVID-19 vaccines for healthy pregnant women and children, which has sparked much ...
1don MSN
Rep. Marjorie Taylor Greene slams FDA green lighting of Moderna's mNEXSPIKE COVID-19 vaccine, describing the move as "Not ...
A team of US researchers has developed a new type of mRNA vaccine that is more scalable and adaptable to tackle continuously ...
Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback